Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Sales (2020 - 2025)

Silence Therapeutics' Return on Sales history spans 6 years, with the latest figure at 22.91% for Q4 2025.

  • On a quarterly basis, Return on Sales rose 2291.0% to 22.91% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.02%, a 3.0% increase, with the full-year FY2025 number at 0.02%, up 3.0% from a year prior.
  • Return on Sales hit 22.91% in Q4 2025 for Silence Therapeutics, up from 1.32% in the prior quarter.
  • Over the last five years, Return on Sales for SLN hit a ceiling of 22.91% in Q4 2025 and a floor of 31.39% in Q1 2021.
  • Historically, Return on Sales has averaged 0.7% across 5 years, with a median of 0.03% in 2022.
  • Biggest five-year swings in Return on Sales: surged 3138bps in 2022 and later tumbled -201bps in 2025.
  • Tracing SLN's Return on Sales over 5 years: stood at 0.03% in 2021, then grew by 4bps to 0.03% in 2022, then crashed by -126bps to 0.07% in 2023, then skyrocketed by 107bps to 0.0% in 2024, then skyrocketed by 471245bps to 22.91% in 2025.
  • Business Quant data shows Return on Sales for SLN at 22.91% in Q4 2025, 1.32% in Q3 2025, and 1.37% in Q2 2025.